var title_f17_2_17440="Traction suture tongue";
var content_f17_2_17440=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Traction suture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A suture can be placed through the anterior portion of the anesthetized tongue to provide tongue traction and better positioning for repair of tongue lacerations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_2_17440=[""].join("\n");
var outline_f17_2_17440=null;
var title_f17_2_17441="Hydrocephalus due to germinal matrix intraventricular hemorrhage";
var content_f17_2_17441=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Hydrocephalus due to germinal matrix intraventricular hemorrhage (IVH) of prematurity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound in an infant with grade IV intraventricular hemorrhage.",
"    <br>",
"     (Panel A) Coronal view.",
"     <br>",
"      (Panel B) Sagittal view.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Drs. Abilash Haridas and Tadanori Tomita.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_2_17441=[""].join("\n");
var outline_f17_2_17441=null;
var title_f17_2_17442="Generating DNA knockout mice";
var content_f17_2_17442=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Generation of target gene for knockout mice",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic of targeting vector and positive/negative selection. A schematic depicting a targeting vector is shown at the top. Plasmid backbone sequences are shown with thin lines. The herpes simplex virus-thymidine kinase (HSV-TK) box represents the negatively selected marker herpes virus thymidine kinase. The hatched boxes represent sequences present in the target gene. The NEOR box represents the positively selected marker neomycin resistance. When this targeting construct is transfected into (embryonic stem) ES cells, a small fraction of the transfected cells will undergo homologous recombination mediated by the target gene sequences included in the vector. This is shown schematically by the Xs representing crossover points. The location of the transcript of the target gene is shown by the heavy black arrow. A double recombination, as pictured, will substitute the neomycin resistance marker for the native portion of the gene lying between the crossover points. This deletion disrupts the gene, thereby \"knocking out\" its function. Positive selection is applied by growing the transfected cells in the presence of G418, a toxic drug that is inactivated by NEOR. Negative selection is applied by growing the transfected cells in the presence of gancyclovir, which is converted to a toxin by HSV-TK. Thus, the population is enriched for cells retaining NEOR and simultaneously losing HSV-TK.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert D Blank, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_2_17442=[""].join("\n");
var outline_f17_2_17442=null;
var title_f17_2_17443="Endothelial function and brachial artery ultrasound";
var content_f17_2_17443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Evaluation of endothelial function with brachial artery ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown is an ultrasound image of the brachial artery at baseline prior to cuff inflation (panel A) and at one minute post-cuff release (panel B). The cuff release resulted in approximately 10 percent improvement in flow-mediated vasodilation of the brachial artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Emile Mohler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_2_17443=[""].join("\n");
var outline_f17_2_17443=null;
var title_f17_2_17444="Aortoduodenal fistula";
var content_f17_2_17444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Aortoduodenal fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CT scan comes from a 75-year-old patient with a history of AAA repair who presented with massive lower gastrointestinal bleeding, and hypotension. An aortoduodenal fistula is demonstrated by a CT scan, which shows a break in the wall of the aorta (arrow) and high density hematoma in the aorta (arrowhead). In image B, air can be seen tracking between the duodenum and the aorta (arrow).",
"    <div class=\"footnotes\">",
"     CT: computed tomography; AAA: abdominal aortic aneurysm; GI: gastrointestinal.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_2_17444=[""].join("\n");
var outline_f17_2_17444=null;
var title_f17_2_17445="Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy";
var content_f17_2_17445=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/2/17445/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/2/17445/contributors\">",
"     Clifford E Kashtan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/2/17445/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/2/17445/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/2/17445/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/2/17445/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/2/17445/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematuria is a common finding in glomerular diseases. This is often associated with other abnormalities including red cell casts, proteinuria, edema, hypertension, and renal insufficiency. In some cases, however, the only manifestation is persistent hematuria similar to that seen with extraglomerular causes of bleeding such as prostatic disease and stones.",
"   </p>",
"   <p>",
"    The patient should initially be reexamined over a period of weeks to months to ascertain that the hematuria is persistent. Transient hematuria is a relatively common finding over time in adults and may be induced by factors such as exercise or infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27973?source=see_link\">",
"     \"Exercise-induced hematuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of a glomerular disease in the patient with persistent hematuria is often suggested by the urinary findings of dysmorphic red cells and an occasional red cell cast. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Glomerular versus nonglomerular bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are three disorders that account for most cases of persistent isolated hematuria due to glomerular disease: IgA nephropathy, hereditary nephritis (Alport syndrome), and thin basement membrane nephropathy (which accounts for most cases of what has been called benign familial hematuria) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/2/17445/abstract/1-6\">",
"     1-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although mild postinfectious glomerulonephritis can also lead to isolated hematuria, there is usually rapid resolution of the urinary abnormalities within three to six months in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H14578038#H14578038\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Hematuria following upper respiratory infection'",
"    </a>",
"    .) Given the increasing availability of genetic testing, additional hematuric syndromes are likely to be described [",
"    <a class=\"abstract\" href=\"UTD.htm?17/2/17445/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgA nephropathy, Alport syndrome, and thin basement membrane nephropathy can often be distinguished by the history [",
"    <a class=\"abstract\" href=\"UTD.htm?17/2/17445/abstract/3-5\">",
"     3-5",
"    </a>",
"    ] and by examining the urine of family members [",
"    <a class=\"abstract\" href=\"UTD.htm?17/2/17445/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gross hematuria is relatively common in IgA nephropathy and Alport syndrome, but is unusual (occurring in less than 10 percent of cases) in thin basement membrane nephropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/2/17445/abstract/3,9\">",
"       3,9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=see_link\">",
"       \"Clinical presentation and diagnosis of IgA nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alport syndrome is typically associated with a family history of renal failure (primarily in males); deafness is also present in many families in which there is an X-linked dominant mode of inheritance [",
"      <a class=\"abstract\" href=\"UTD.htm?17/2/17445/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"       \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A family history of hematuria is also common in thin basement membrane nephropathy (typically with autosomal dominant inheritance) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/2/17445/abstract/9\">",
"       9",
"      </a>",
"      ], but occurs in only isolated cases of IgA nephropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/2/17445/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12088?source=see_link\">",
"       \"Thin basement membrane nephropathy (benign familial hematuria)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A patient with episodes of gross hematuria but a negative family history is most likely to have IgA nephropathy.",
"     </li>",
"     <li>",
"      A patient with only persistent microscopic hematuria and the finding of hematuria but not renal failure in family members is most likely to have thin basement membrane nephropathy.",
"     </li>",
"     <li>",
"      A patient with a family history of renal failure and in some cases deafness probably has Alport syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative frequency of these disorders also varies with the population that is studied [",
"    <a class=\"abstract\" href=\"UTD.htm?17/2/17445/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. In most countries, for example, IgA nephropathy and thin basement membrane nephropathy account for the majority of cases of isolated glomerular hematuria [",
"    <a class=\"abstract\" href=\"UTD.htm?17/2/17445/abstract/13,14,16\">",
"     13,14,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The definitive diagnosis can be established by renal biopsy or in some instances, skin biopsy or genetic testing (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    ). However, additional testing is frequently not indicated, since the likelihood of finding a treatable disease in isolated glomerular hematuria is very low. In one report, for example, performance of renal biopsy in this setting led to a change in management in only one of 36 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/2/17445/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, confirmation via a renal biopsy that glomerular hematuria is due to IgA nephropathy, or thin basement membrane nephropathy may not be necessary:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgA nephropathy &mdash; There is no conclusive evidence to support any therapy in patients with IgA nephropathy and isolated hematuria. Although patients with IgA nephropathy may progress to renal failure, those who have only isolated hematuria (with little or no proteinuria) do very well unless they develop signs of progressive disease (such as increasing levels of proteinuria, blood pressure, or serum creatinine concentration) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/2/17445/abstract/18\">",
"       18",
"      </a>",
"      ]. Thus, close periodic monitoring of the urinalysis, renal function, and protein excretion is sufficient in most cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42106?source=see_link\">",
"       \"Treatment and prognosis of IgA nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thin basement membrane nephropathy &mdash; Thin basement membrane nephropathy also typically has a benign course. However, a biopsy may be indicated in patients with suspected thin basement membrane nephropathy and isolated hematuria who subsequently develop hypertension or proteinuria [",
"      <a class=\"abstract\" href=\"UTD.htm?17/2/17445/abstract/15\">",
"       15",
"      </a>",
"      ]. The results of one study, for example, suggest that the presence of microalbuminuria in a patient with microscopic hematuria was associated with an increased likelihood of discovering IgA nephropathy on kidney biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/2/17445/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12088?source=see_link\">",
"       \"Thin basement membrane nephropathy (benign familial hematuria)\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Individuals with thin basement membrane nephropathy frequently have heterozygous mutations in either COL4A3 or COL4A4, the genes that respectively encode the alpha-3 and alpha-4 chains of type IV collagen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12088?source=see_link\">",
"       \"Thin basement membrane nephropathy (benign familial hematuria)\"",
"      </a>",
"      .)&nbsp;In some families with thin basement nephropathy and heterozygous mutations of COL4A3 or COL4A4, affected individuals are at risk for proteinuria and renal insufficiency&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?17/2/17445/abstract/20\">",
"       20",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Sequencing of COL4A3 and COL4A4 is commercially available in Europe and in the United States (see&nbsp;",
"      <a class=\"external\" href=\"file://www.genereviews.org/\">",
"       www.genereviews.org",
"      </a>",
"      ). Confirmation of a diagnosis of thin basement membrane nephropathy is not necessary if suspicion is high on the basis of clinical findings and pedigree data.",
"     </li>",
"     <li>",
"      Alport syndrome &mdash; Confirmation of Alport syndrome by kidney or skin biopsy or by genetic testing has important implications for the patient's prognosis and for genetic counseling. A skin biopsy is a relatively noninvasive way to establish the diagnosis of X-linked Alport syndrome. Incubation of the biopsy specimen with a monoclonal antibody directed against the alpha-5 chain of type IV collagen (which is the site of the primary abnormality in hereditary nephritis) reveals no staining along the epidermal basement membrane in most males with X-linked Alport syndrome, discontinuous staining in most female carriers, but normal staining in autosomal forms of Alport syndrome, thin basement membrane nephropathy and other glomerular disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?17/2/17445/abstract/21\">",
"       21",
"      </a>",
"      ]. However, normal immunostaining for the alpha-5(IV) chain in epidermal basement membrane does not exclude a diagnosis of Alport syndrome. Immunostaining of kidney biopsies for the alpha-3, alpha-4, and alpha-5 chains of type IV collagen can confirm a diagnosis of Alport syndrome and frequently distinguish between X-linked and autosomal recessive disease. Sequencing of the COL4A5 gene, which encodes the alpha-5 chain, is commercially available in the United States and Europe. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"       \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      About 10 percent of individuals with X-linked Alport syndrome have de novo mutations, so the absence of a family history of hematuria or renal failure does not exclude the diagnosis. In children with persistent glomerular hematuria, kidney biopsy is frequently performed to establish a specific diagnosis, unless family history strongly suggests thin basement membrane nephropathy or Alport syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/59/23474?source=see_link\">",
"       \"Patient information: Blood in the urine (hematuria) in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/53/10066?source=see_link\">",
"       \"Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/35/37426?source=see_link\">",
"       \"Patient information: Glomerular disease overview (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three disorders account for most cases of persistent isolated hematuria due to glomerular disease: IgA nephropathy, Alport syndrome, and thin basement membrane nephropathy. These conditions can often be distinguished by the history and by examining the urine of asymptomatic family members. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of a family history of renal failure, isolated glomerular hematuria typically has a benign outcome. As a result, the performance of a renal biopsy is often not indicated in this setting, since the likelihood of finding a treatable disease in isolated glomerular hematuria is very low. However, kidney biopsy is frequently performed in male children with persistent glomerular hematuria and no family history of renal failure because 10 percent of individuals with X-linked Alport syndrome have de novo mutations. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients who present with isolated hematuria will develop hypertension",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      proteinuria over time, and will be at increased risk for development of renal insufficiency. Patients with isolated glomerular hematuria should undergo regular measurement of blood pressure and screening for proteinuria, to help identify candidates for early intervention. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=see_link\">",
"       \"Clinical presentation and diagnosis of IgA nephropathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"       \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12088?source=see_link\">",
"       \"Thin basement membrane nephropathy (benign familial hematuria)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/1\">",
"      Topham PS, Harper SJ, Furness PN, et al. Glomerular disease as a cause of isolated microscopic haematuria. Q J Med 1994; 87:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/2\">",
"      Tiebosch AT, Wolters J, Frederik PF, et al. Epidemiology of idiopathic glomerular disease: a prospective study. Kidney Int 1987; 32:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/3\">",
"      Tiebosch AT, Frederik PM, van Breda Vriesman PJ, et al. Thin-basement-membrane nephropathy in adults with persistent hematuria. N Engl J Med 1989; 320:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/4\">",
"      Trachtman H, Weiss RA, Bennett B, Greifer I. Isolated hematuria in children: indications for a renal biopsy. Kidney Int 1984; 25:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/5\">",
"      Auwardt R, Savige J, Wilson D. A comparison of the clinical and laboratory features of thin basement membrane disease (TBMD) and IgA glomerulonephritis (IgA GN). Clin Nephrol 1999; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/6\">",
"      Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003; 348:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/7\">",
"      Plaisier E, Alamowitch S, Gribouval O, et al. Autosomal-dominant familial hematuria with retinal arteriolar tortuosity and contractures: a novel syndrome. Kidney Int 2005; 67:2354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/8\">",
"      Blumenthal SS, Fritsche C, Lemann J Jr. Establishing the diagnosis of benign familial hematuria. The importance of examining the urine sediment of family members. JAMA 1988; 259:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/9\">",
"      Aarons I, Smith PS, Davies RA, et al. Thin membrane nephropathy: a clinico-pathological study. Clin Nephrol 1989; 32:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/10\">",
"      Flinter FA, Cameron JS, Chantler C, et al. Genetics of classic Alport's syndrome. Lancet 1988; 2:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/11\">",
"      Kashtan CE. Alport syndrome and thin glomerular basement membrane disease. J Am Soc Nephrol 1998; 9:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/12\">",
"      Julian BA, Quiggins PA, Thompson JS, et al. Familial IgA nephropathy. Evidence of an inherited mechanism of disease. N Engl J Med 1985; 312:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/13\">",
"      Yamagata K, Yamagata Y, Kobayashi M, Koyama A. A long-term follow-up study of asymptomatic hematuria and/or proteinuria in adults. Clin Nephrol 1996; 45:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/14\">",
"      Tanaka H, Kim ST, Takasugi M, Kuroiwa A. Isolated hematuria in adults: IgA nephropathy is a predominant cause of hematuria compared with thin glomerular basement membrane nephropathy. Am J Nephrol 1996; 16:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/15\">",
"      van Paassen P, van Breda Vriesman PJ, van Rie H, Tervaert JW. Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease-The Limburg Renal Registry. Kidney Int 2004; 66:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/16\">",
"      Iseki K, Miyasato F, Uehara H, et al. Outcome study of renal biopsy patients in Okinawa, Japan. Kidney Int 2004; 66:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/17\">",
"      Richards NT, Darby S, Howie AJ, et al. Knowledge of renal histology alters patient management in over 40% of cases. Nephrol Dial Transplant 1994; 9:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/18\">",
"      Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001; 110:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/19\">",
"      Eardley KS, Ferreira MA, Howie AJ, et al. Urinary albumin excretion: a predictor of glomerular findings in adults with microscopic haematuria. QJM 2004; 97:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/20\">",
"      Voskarides K, Damianou L, Neocleous V, et al. COL4A3/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy. J Am Soc Nephrol 2007; 18:3004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/2/17445/abstract/21\">",
"      Yoshioka K, Hino S, Takemura T, et al. Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody. Am J Pathol 1994; 144:986.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3053 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_2_17445=[""].join("\n");
var outline_f17_2_17445=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=related_link\">",
"      Clinical presentation and diagnosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27973?source=related_link\">",
"      Exercise-induced hematuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=related_link\">",
"      Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/53/10066?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/59/23474?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/35/37426?source=related_link\">",
"      Patient information: Glomerular disease overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12088?source=related_link\">",
"      Thin basement membrane nephropathy (benign familial hematuria)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42106?source=related_link\">",
"      Treatment and prognosis of IgA nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_2_17446="Diversion colitis Light";
var content_f17_2_17446=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Diversion colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power view of a colonic biopsy from a child with diversion colitis reveals reactive lymphoid hyperplasia expanding the mucosa and submucosa, and an increased number of lymphocytes and plasma cells in the upper half of the mucosa. The crypts are slightly disordered, atrophic, and regenerative in appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_2_17446=[""].join("\n");
var outline_f17_2_17446=null;
var title_f17_2_17447="Pravastatin: Pediatric drug information";
var content_f17_2_17447=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pravastatin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"    see \"Pravastatin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/21/37204?source=see_link\">",
"    see \"Pravastatin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16054981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      HMG-CoA Reductase Inhibitors and Risk of Increased Blood Glucose Concentrations and Diabetes",
"     </span>",
"     <span class=\"collapsible-date\">",
"      January 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has notified healthcare professionals of updates to the product monographs of HMG-CoA reductase inhibitors (aka, &ldquo;statins&rdquo;) marketed in Canada regarding the risk of increased blood glucose concentrations and a small increased risk of diabetes mellitus following administration of these agents. The risk appears to be greatest in patients already at risk for diabetes (eg, patients with increased blood glucose concentration, hypertriglyceridemia, obesity, hypertension).  However, Health Canada continues to acknowledge that the benefits of statin therapy far outweigh the risk of dysglycemia. It is recommended that clinicians carefully monitor the use of statins in patients at high risk of developing diabetes mellitus.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/16949a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pravachol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F212523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Pravastatin&reg;;",
"     </li>",
"     <li>",
"      CO Pravastatin;",
"     </li>",
"     <li>",
"      Dom-Pravastatin;",
"     </li>",
"     <li>",
"      JAMP-Pravastatin;",
"     </li>",
"     <li>",
"      Mint-Pravastatin;",
"     </li>",
"     <li>",
"      Mylan-Pravastatin;",
"     </li>",
"     <li>",
"      Novo-Pravastatin;",
"     </li>",
"     <li>",
"      Nu-Pravastatin;",
"     </li>",
"     <li>",
"      PHL-Pravastatin;",
"     </li>",
"     <li>",
"      PMS-Pravastatin;",
"     </li>",
"     <li>",
"      Pravachol&reg;;",
"     </li>",
"     <li>",
"      RAN&trade;-Pravastatin;",
"     </li>",
"     <li>",
"      ratio-Pravastatin;",
"     </li>",
"     <li>",
"      Riva-Pravastatin;",
"     </li>",
"     <li>",
"      Sandoz-Pravastatin;",
"     </li>",
"     <li>",
"      Teva-Pravastatin;",
"     </li>",
"     <li>",
"      ZYM-Pravastatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antilipemic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HMG-CoA Reductase Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"      see \"Pravastatin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage should be individualized according to the baseline LDL-C level, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents: Oral:",
"     <b>",
"      Hyperlipidemia or heterozygous familial and nonfamilial hypercholesterolemia: Note:",
"     </b>",
"     Begin treatment if after adequate trial of diet the following are present: LDL-C &ge;190 mg/dL or LDL-C remains &ge;160 mg/dL and positive family history of premature cardiovascular disease or meets NCEP classification. (NHLBI 2011). Therapy may be considered for children 8-9 years of age meeting the above criteria or for children with diabetes mellitus and LDL-C &ge;130 mg/dL (Daniels, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adolescents 8-13 years: 20 mg once daily; doses &gt;20 mg have not been studied",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents 14-18 years: 40 mg once daily; doses &gt;40 mg have not been studied",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Hyperlipidemias, primary prevention of coronary events, secondary prevention of cardiovascular events:",
"     </b>",
"     Oral: Initial: 40 mg once daily; titrate dosage to response (usual range: 10-80 mg) (maximum daily dose: 80 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adults: Significant impairment: Initiate dosage at 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer labeling; contraindicated in active liver disease or in patients with unexplained persistent elevations of serum transaminases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment for pravastatin with concomitant medications:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clarithromycin: Maximum daily dose: 40 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cyclosporine: Initial: 10 mg pravastatin daily at bedtime; titrate with caution (maximum daily dose: 20 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F212496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sodium: 10 mg, 20 mg, 40 mg, 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pravachol&reg;: 20 mg, 40 mg, 80 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F212481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be taken without regard to meals or time of day. Give at least 1 hour before or 4 hours after bile acid resins.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1061334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F), excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light and moisture; dispense in a tightly closed container.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to dietary therapy in patients with heterozygous familial hypercholesterolemia (HFH) hypercholesterolemia if LDL-C remains &ge;190 mg/dL or if &ge;160 mg/dL with family history of premature cardiovascular (CVD) or presence of &ge;2 cardiovascular risk [FDA approved in children &ge;8 years of age and adolescents]. Adjunct to dietary therapy to decrease elevated serum total and low density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo-B), and triglyceride levels, and to increase high density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia (heterozygous, familial, and nonfamilial) and mixed dyslipidemia (Fredrickson types IIa and IIb) (FDA approved in adults); adjunct to dietary therapy in patients with isolated hypertriglyceridemia (Fredrickson type IV) (FDA approved in adults); treatment of primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet (FDA approved in adults); primary and secondary prevention of cardiovascular disease in high risk patients (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Primary prevention of cardiovascular disease in high-risk patients (FDA approved in adults); risk factors include: Age &ge;55 years, smoking, hypertension, low HDL-C, or family history of early coronary heart disease; secondary prevention of cardiovascular disease to reduce the risk of MI, stroke, revascularization procedures, and angina in patients with evidence of coronary heart disease.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F212578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pravachol&reg; may be confused with atorvaSTATin, Prevacid&reg;, Prinivil&reg;, propranolol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pravastatin may be confused with nystatin, pitavastatin, prasugrel",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F212576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, heartburn, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Influenza",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergy, amnesia (reversible), anaphylaxis, angioedema, cholestatic jaundice, cirrhosis, cognitive impairment (reversible), confusion (reversible), cranial nerve dysfunction, dermatomyositis, erythema multiforme, ESR increase, fulminant hepatic necrosis, gynecomastia, hemolytic anemia, hepatitis, hepatoma, lens opacity, libido change, lupus erythematosus-like syndrome, memory disturbance (reversible), memory impairment (reversible), muscle weakness, myopathy, neuropathy, pancreatitis, paresthesia, peripheral nerve palsy, polymyalgia rheumatica, positive ANA, purpura, rhabdomyolysis, Stevens-Johnson syndrome, taste disturbance, tremor, vasculitis, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Additional class-related events or case reports (not necessarily reported with pravastatin therapy): Angioedema, blood glucose increased, cataracts, depression, diabetes mellitus (new onset), dyspnea, eosinophilia, erectile dysfunction, facial paresis, glycosylated hemoglobin (Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     ) increased, hypersensitivity reaction, immune-mediated necrotizing myopathy (IMNM), impaired extraocular muscle movement, impotence, interstitial lung disease, leukopenia, malaise, memory loss, ophthalmoplegia, paresthesia, peripheral neuropathy, photosensitivity, psychic disturbance, skin discoloration, thrombocytopenia, thyroid dysfunction, toxic epidermal necrolysis, transaminases increased, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pravastatin or any component; active liver disease; unexplained persistent elevations of serum transaminases; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases in Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however, the benefits of statin therapy far outweigh the risk of dysglycemia. Secondary causes of hyperlipidemia should be ruled out prior to therapy; has not been studied in conditions where the major abnormality is elevation of chylomicrons (hyperlipoproteinemia Types I or V). Use caution in patients with conditions or on medications that reduce steroidogenesis (eg, ketoconazole, spironolactone, cimetidine).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Although rare, reversible cognitive impairment (including confusion, forgetfulness, amnesia, and memory loss) can occur with HMG-CoA reductase inhibitors. These cognitive symptoms have been reported at variable times during therapy (1 day to years after initiation) and are reversible with discontinuation; resolution usually occurs within ~3 weeks. Cases have not been associated with fixed or progressive dementia; nor have they been associated with age, specific HMG-CoA reductase inhibitor, dose, or concomitant medication use.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients receiving HMG-CoA reductase inhibitors have developed rhabdomyolysis with or without acute renal failure and/or myopathy; patients should be monitored closely; risk is dose related and is increased with concurrent use of other lipid-lowering medications (eg, fibric acid derivatives or niacin at doses &gt;1 g/day). With concurrent use of erythromycin, clarithromycin, or cyclosporine; consider dosage reductions of pravastatin. Ensure patient is on the lowest effective pravastatin dose in all circumstances. Discontinue in any patient in which CPK levels are markedly elevated (&gt;10 times ULN) or if myopathy is suspected/diagnosed; monitoring of CPK may be warranted, but may not prevent severe myopathy. The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure (eg, sepsis, hypotension, trauma, uncontrolled seizures). However, based upon current evidence, HMG-CoA reductase inhibitor therapy should be continued in the perioperative period unless risk outweighs cardioprotective benefit. Use caution in patients with renal impairment, inadequately treated hypothyroidism, and those taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An autoimmune-mediated myopathy (IMNM) has been reported (rarely) with HMG-CoA reductase inhibitor therapy; presents as proximal muscle weakness with elevated CPK levels, which persists despite discontinuation of HMG-CoA reductase inhibitor therapy; additionally, muscle biopsy may show necrotizing myopathy with limited inflammation; immunosuppressive therapy (eg, corticosteroids, azathioprine) may be used for treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Postmarketing reports of fatal and nonfatal hepatic failure are rare; if serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy. If an alternate etiology is not identified, do not restart pravastatin. Liver enzyme tests should be obtained at baseline and as clinically indicated; routine periodic monitoring of liver enzymes is not necessary. Use with caution in patients with history of heavy alcohol use or a previous history of liver disease",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F212564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor), P-glycoprotein, SLCO1B1;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F212490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Pravastatin. Management: Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Pravastatin. Pravastatin may increase the serum concentration of CycloSPORINE (Systemic). Management: Limit pravastatin to 20 mg/day in patients who are also receiving cyclosporine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of Pravastatin. This effect has only been demonstrated with darunavir/ritonavir. The individual contributions of darunavir and ritonavir are unknown.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use of HMG-CoA reductase inhibitors (statins) with fusidic acid if possible.  If treatment with fusidic acid is necessary, consider temporarily stopping the statin.  With any concurrent use monitor patients closely for statin toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of Pravastatin. Gemfibrozil may increase the serum concentration of Pravastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: HMG-CoA Reductase Inhibitors may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: May decrease the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PARoxetine: Pravastatin may enhance the adverse/toxic effect of PARoxetine. Specifically, blood glucose elevations may occur with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in this interaction.  There is a lack of data regarding the risk with other statins, but caution appears warranted with any statins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May decrease the serum concentration of Pravastatin. This effect has only been demonstrated with saquinavir/ritonavir. The individual contributions of saquinavir and ritonavir are unknown.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trabectedin: HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F16355654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food decreases systemic bioavailability, but does not decrease efficacy.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F212492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F212506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholesterol biosynthesis may be important in fetal development. Contraindicated in pregnancy. Administer to women of childbearing potential only when conception is highly unlikely and patients have been informed of potential hazards.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pediatric  patients: Baseline: ALT, AST, and creatine phosphokinase levels (CPK); fasting lipid panel (FLP) and repeat ALT and AST should be checked after 4 weeks of therapy; if no myopathy symptoms or laboratory abnormalities, then monitor FLP, ALT, and AST every 3-4 months during the first year and then every 6 months thereafter (NHLBI, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: Baseline CPK (recheck CPK in any patient with symptoms suggestive of myopathy; discontinue therapy if markedly elevated); baseline liver function tests (LFTs) and repeat when clinically indicated thereafter. Patients with elevated transaminase levels should have a second (confirmatory) test and frequent monitoring until values normalize; discontinue if increase in ALT/AST is persistently &gt;3 times ULN (NCEP, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lipid panel (total cholesterol, HDL, LDL, triglycerides):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ATP III recommendations (NCEP, 2002): Baseline; 6-8 weeks after initiation of drug therapy; if dose increased, then at 6-8 weeks until final dose determined. Once treatment goal achieved, follow-up intervals may be reduced to every 4-6 months. Lipid panel should be assessed at least annually, and preferably at each clinic visit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer recommendation: Analyze lipid panel at initiation and 4 weeks after each titration.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pravastatin is a selective, competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1061344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: After 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     LDL-reduction: 40 mg/day: 34% (for each doubling of this dose, LDL-C is lowered by &sim;6%)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1061345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 34%; Rapidly absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.46 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic  to multiple metabolites; primary metabolite is 3&alpha;-hydroxy-iso-pravastatin (2.5% to 10% activity of parent drug); extensive first-pass metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Absolute: 17%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents (4.9-15.6 years): 1.6 hours; range: 0.85-4.2 hours (Hedman, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 77 hours (including all metabolites); pravastatin: 2.3 hours; 3&alpha;-hydroxy-iso-pravastatin: ~1.5 hours (Gustavson, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &sim;20% excreted in urine unchanged and 70% in feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1061336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/21/37204?source=see_link\">",
"      see \"Pravastatin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rare photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching) have been reported with similar  medications. Report severe and unresolved gastric upset, any vision changes, muscle pain and weakness, changes in color of urine or stool, yellowing of skin or eyes, and any unusual bruising. Female patients of childbearing age must be counseled to use two effective forms of contraception simultaneously, unless absolute abstinence is the chosen method; this drug may cause severe fetal defects. Avoid the herbal medicine St John's wort. This drug does not eliminate the need for prescribed diet or exercise regimen.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Daniels SR, Greer FR, and Committee on Nutrition, \"Lipid Screening and Cardiovascular Health in Childhood,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 122(1):198-208.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/2/17447/abstract-text/18596007/pubmed\" id=\"18596007\" target=\"_blank\">",
"        18596007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gustavson LE, Schweitzer SM, Koehne-Voss S, et al, \"The Effects of Multiple Doses of Fenofibrate on the Pharmacokinetics of Pravastatin and Its 3Alpha-hydroxy Isomeric Metabolite,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2005, 45(8):947-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/2/17447/abstract-text/16027406/pubmed\" id=\"16027406\" target=\"_blank\">",
"        16027406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hedman M, Neuvonen PJ, Neuvonen M, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Pravastatin in Children With Familial Hypercholesterolemia,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2003, 74(2):178-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/2/17447/abstract-text/12891228 /pubmed\" id=\"12891228 \" target=\"_blank\">",
"        12891228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCrindle BW, Urbina EM, Dennison BA, et al, \"Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115(14):1948-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/2/17447/abstract-text/17377073/pubmed\" id=\"17377073\" target=\"_blank\">",
"        17377073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Heart, Lung, and Blood Institute, \"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,\" Clinical Practice Guidelines, 2011, National Institutes of Health. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf%20\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodenburg J, Vissers MN, Wiegman A, et al, \"Statin Treatment in Children With Familial Hypercholesterolemia: The Younger, the Better,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(6):664-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/2/17447/abstract-text/17664376/pubmed\" id=\"17664376\" target=\"_blank\">",
"        17664376",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo; May 2001, www.nhlbi.nih.gov/guidelines/cholesterol.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiegman A, Hutten BA, de Groot E, et al, &ldquo;Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 292(3):331-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/2/17447/abstract-text/15265847/pubmed\" id=\"15265847\" target=\"_blank\">",
"        15265847",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12913 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-EBC78AF0D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_2_17447=[""].join("\n");
var outline_f17_2_17447=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16054981\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212522\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212523\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061338\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061331\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212496\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212481\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061342\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061334\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061341\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212578\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212576\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061346\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061330\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061329\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212564\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212490\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16355654\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212492\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212506\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061337\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061328\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061344\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061345\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061336\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12913\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12913|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=related_link\">",
"      Pravastatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/21/37204?source=related_link\">",
"      Pravastatin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_2_17448="Brown syndrome";
var content_f17_2_17448=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Brown syndrome left eye",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 399px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Limited elevation of the left eye in adduction. B) Normal elevation in abduction. C) Because the eyes are straight in the primary position, there is no compensatory face turn. D) In straight upgaze, there is divergence of the eyes, a V pattern, as the left eye \"looks around\" the restricted area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &copy;2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_2_17448=[""].join("\n");
var outline_f17_2_17448=null;
var title_f17_2_17449="Cardiovascular event vs LV mass";
var content_f17_2_17449=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The risk of a cerebrovascular event in hypertensives is related to left ventricular mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 402px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 1033 hypertensive subjects the age-adjusted five-year probability of cerebrovascular events is related to left ventricular mass, as assessed with echocardiography.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Verdecchia, P, Porcellati, C, Reboldi, G, et al, Circulation 2001; 104:2039.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_2_17449=[""].join("\n");
var outline_f17_2_17449=null;
var title_f17_2_17450="Ethinyl estradiol and levonorgestrel: Drug information";
var content_f17_2_17450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"22\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ethinyl estradiol and levonorgestrel: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/43/22198?source=see_link\">",
"    see \"Ethinyl estradiol and levonorgestrel: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Altavera&trade;;",
"     </li>",
"     <li>",
"      Amethia&trade;;",
"     </li>",
"     <li>",
"      Amethia&trade; Lo;",
"     </li>",
"     <li>",
"      Amethyst&trade;;",
"     </li>",
"     <li>",
"      Aviane&trade;;",
"     </li>",
"     <li>",
"      camrese&trade;;",
"     </li>",
"     <li>",
"      Chateal&trade;;",
"     </li>",
"     <li>",
"      Enpresse&reg;;",
"     </li>",
"     <li>",
"      Falmina&trade;;",
"     </li>",
"     <li>",
"      Introvale&trade;;",
"     </li>",
"     <li>",
"      Jolessa&trade;;",
"     </li>",
"     <li>",
"      Kurvelo&trade;;",
"     </li>",
"     <li>",
"      Lessina&reg;;",
"     </li>",
"     <li>",
"      Levonest&trade;;",
"     </li>",
"     <li>",
"      Levora&reg;;",
"     </li>",
"     <li>",
"      LoSeasonique&reg;;",
"     </li>",
"     <li>",
"      Lutera&reg;;",
"     </li>",
"     <li>",
"      Lybrel&reg;;",
"     </li>",
"     <li>",
"      Marlissa;",
"     </li>",
"     <li>",
"      Myzilra&trade;;",
"     </li>",
"     <li>",
"      Nordette&reg; 28 [DSC];",
"     </li>",
"     <li>",
"      Orsythia&trade;;",
"     </li>",
"     <li>",
"      Portia&reg;;",
"     </li>",
"     <li>",
"      Quasense&reg;;",
"     </li>",
"     <li>",
"      Seasonale&reg; [DSC];",
"     </li>",
"     <li>",
"      Seasonique&reg;;",
"     </li>",
"     <li>",
"      Sronyx&reg;;",
"     </li>",
"     <li>",
"      Trivora&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alesse&reg;;",
"     </li>",
"     <li>",
"      Aviane&reg;;",
"     </li>",
"     <li>",
"      Min-Ovral&reg;;",
"     </li>",
"     <li>",
"      Seasonale&reg;;",
"     </li>",
"     <li>",
"      Triphasil&reg;;",
"     </li>",
"     <li>",
"      Triquilar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F168351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Contraceptive;",
"     </li>",
"     <li>",
"      Estrogen and Progestin Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F168335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Contraception, 28-day cycle:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Schedule 1 (Sunday starter): Dose begins on first Sunday after onset of menstruation; if the menstrual period starts on Sunday, take first tablet that very same day. With a Sunday start, an additional method of contraception should be used until after the first 7 days of consecutive administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For 21-tablet package: 1 tablet/day for 21 consecutive days, followed by 7 days off of the medication; a new course begins on the 8th day after the last tablet is taken",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For 28-tablet package: 1 tablet/day without interruption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Schedule 2 (Day-1 starter): Dose starts on first day of menstrual cycle taking 1 tablet/day:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For 21-tablet package: 1 tablet/day for 21 consecutive days, followed by 7 days off of the medication; a new course begins on the 8th day after the last tablet is taken",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For 28-tablet package: 1 tablet/day without interruption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If all doses have been taken on schedule and one menstrual period is missed, continue dosing cycle. If two consecutive menstrual periods are missed, pregnancy test is required before new dosing cycle is started.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Missed doses",
"     <b>",
"      monophasic formulations",
"     </b>",
"     (refer to package insert for complete information):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     One dose missed: Take as soon as remembered or take 2 tablets next day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Two consecutive doses missed in the first 2 weeks: Take 2 tablets as soon as remembered or 2 tablets next 2 days. An additional method of contraception should be used for 7 days after missed dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Two consecutive doses missed in week 3 or three consecutive doses missed at any time: An additional method of contraception must be used for 7 days after a missed dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 1 (Sunday starter): Continue dose of 1 tablet daily until Sunday, then discard the rest of the pack, and a new pack should be started that same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 2 (Day-1 starter): Current pack should be discarded, and a new pack should be started that same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Missed doses",
"     <b>",
"      biphasic/triphasic formulations",
"     </b>",
"     (refer to package insert for complete information):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     One dose missed: Take as soon as remembered or take 2 tablets next day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Two consecutive doses missed in week 1 or week 2 of the pack: Take 2 tablets as soon as remembered and 2 tablets the next day. Resume taking 1 tablet daily until the pack is empty. An additional method of contraception should be used for 7 days after a missed dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Two consecutive doses missed in week 3 of the pack: An additional method of contraception must be used for 7 days after a missed dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 1 (Sunday starter): Take 1 tablet every day until Sunday. Discard the remaining pack and start a new pack of pills on the same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 2 (Day-1 starter): Discard the remaining pack and start a new pack the same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Three or more consecutive doses missed: An additional method of contraception must be used for 7 days after a missed dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 1 (Sunday starter): Take 1 tablet every day until Sunday; on Sunday, discard the pack and start a new pack.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 2 (Day-1 starter): Discard the remaining pack and begin new pack of tablets starting on the same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Contraception, 91-day cycle (extended cycle regimen):",
"     </b>",
"     Dose begins on first Sunday after onset of menstruation; if the menstrual period starts on Sunday, take first tablet that very same day. An additional method of contraception should be used until after the first 7 days of consecutive administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Seasonale&reg;: One active tablet/day for 84 consecutive days, followed by 1 inactive tablet/day for 7 days; if all doses have been taken on schedule and one menstrual period is missed, pregnancy should be ruled out prior to continuing therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Seasonique&reg;, LoSeasonique&reg;: One active tablet/day for 84 consecutive days, followed by 1 low dose estrogen tablet/day for 7 days; if all doses have been taken on schedule and one menstrual period is missed, pregnancy should be ruled out prior to continuing therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Missed doses:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     One dose missed: Take as soon as remembered or take 2 tablets the next day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Two consecutive doses missed: Take 2 tablets as soon as remembered or 2 tablets the next 2 days. An additional nonhormonal method of contraception should be used for 7 consecutive days after the missed dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Three or more consecutive doses missed: Do not take the missed doses; continue taking 1 tablet/day until pack is complete. Bleeding may occur during the following week. An additional nonhormonal method of contraception should be used for 7 consecutive days after the missed dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Any number of pills during week 13: Throw away the missed pills and keep taking scheduled pills until the pack is finished. A back-up method of contraception is not needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Contraception, continuous use (extended cycle regimen):",
"     </b>",
"     Oral: Lybrel&reg;: Take one tablet daily, at the same time each day, without a tablet-free interval. Therapy should be initiated as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     No previous contraception: Begin on the first day of menstrual cycle. Back-up contraception is not needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Previously taking a 21-day or 28-day combination hormonal contraceptive: Begin on day 1 of the withdrawal bleed (at the latest, 7 days after the last active tablet). Back-up contraception is not needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Previously using a progestin-only pill: Begin the day after taking a progestin only pill. Back-up contraception is needed for the first 7 days of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Previously using contraceptive implant: Begin the day of implant removal. Back-up contraception is needed for the first 7 days of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Previously using contraceptive injection: Begin when the next injection is due. Back-up contraception is needed for the first 7 days of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Missed doses:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     One dose missed: Take as soon as remembered then take the next tablet at the regular time (2 tablets in 1 day). An additional nonhormonal method of contraception should also be used for 7 consecutive days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Two consecutive doses missed: If remembered the day of the second missed tablet, take 2 tablets as soon as remembered, then 1 tablet the next day. If remembered the day after the second tablet is missed, take 2 tablets the day remembered, then 2 tablets the next day. An additional nonhormonal method of contraception should also be used for 7 consecutive days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Three or more consecutive doses missed: Take 1 tablet daily and contact healthcare provider; do not take the missed pills. An additional nonhormonal method of contraception should also be used for 7 consecutive days.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F168345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females: Contraception or emergency contraception: Oral: Refer to adult dosing; not to be used prior to menarche.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F168336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Specific guidelines not available; use with caution and monitor blood pressure closely. Consider other forms of contraception.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F168337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F168313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [low-dose formulation]: Ethinyl estradiol 0.02 mg and levonorgestrel 0.1 mg [21 tablets and 7 inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aviane&trade;: Ethinyl estradiol 0.02 mg and levonorgestrel 0.1 mg [21 orange tablets and 7 light green inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Falmina&trade;: Ethinyl estradiol 0.02 mg and levonorgestrel 0.1 mg [21 orange tablets and 7 white inactive tablets] (28s) [contains soya lecithin, tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lessina&reg;: Ethinyl estradiol 0.02 mg and levonorgestrel 0.1 mg [21 pink tablets and 7 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lutera&reg;, Sronyx&reg;: Ethinyl estradiol 0.02 mg and levonorgestrel 0.1 mg [21 white tablets and 7 peach inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orsythia&trade;: Ethinyl estradiol 0.02 mg and levonorgestrel 0.1 mg [21 pink tablets and 7 light green inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Tablet, oral [monophasic formulation]: Ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg [21 tablets and 7 inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Altavera&trade;: Ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg [21 peach tablets and 7 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chateal&trade;: Ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg [21 white tablets and 7 green inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kurvelo&trade;: Ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg [21 light orange tablets and 7 pink inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levora&reg;: Ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg [21 white tablets and 7 peach inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Marlissa: Ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg [21 light orange tablets and 7 pink inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nordette&reg; 28: Ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg [21 light orange tablets and 7 pink inactive tablets] (28s) [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Portia&reg; 28: Ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg [21 pink tablets and 7 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Tablet, oral [extended cycle regimen]: Ethinyl estradiol 0.02 mg and levonorgestrel 0.1 mg [84 tablets] and ethinyl estradiol 0.01 mg [7 tablets] (91s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amethia&trade;: Ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg [84 white tablets] and ethinyl estradiol 0.01 mg [7 light blue tablets] (91s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amethia&trade; Lo: Ethinyl estradiol 0.02 mg and levonorgestrel 0.1 mg [84 white tablets] and ethinyl estradiol 0.01 mg [7 blue tablets] (91s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     camrese&trade;: Ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg [84 light blue-green tablets] and ethinyl estradiol 0.01 mg [7 yellow tablets] (91s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Introvale&trade;: Ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg [84 peach tablets and 7 white inactive tablets] (91s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Jolessa&trade;, Seasonale&reg; [DSC]: Ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg [84 pink tablets and 7 white inactive tablets] (91s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LoSeasonique&reg;: Ethinyl estradiol 0.02 mg and levonorgestrel 0.1 mg [84 orange tablets] and ethinyl estradiol 0.01 mg [7 yellow tablets] (91s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Quasense&reg;: Ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg [84 white tablets and 7 peach inactive tablets] (91s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Seasonique&reg;: Ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg [84 light blue-green tablets] and ethinyl estradiol 0.01 mg [7 yellow tablets] (91s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Tablet, oral [noncyclic regimen]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Amethyst&trade;:  Ethinyl estradiol 0.02 mg and levonorgestrel 0.09 mg [28 white tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Lybrel&reg;:  Ethinyl estradiol 0.02 mg and levonorgestrel 0.09 mg [28 yellow tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Tablet, oral [triphasic formulation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enpresse&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-6: Ethinyl estradiol 0.03 mg and levonorgestrel 0.05 mg [6 pink tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 7-11: Ethinyl estradiol 0.04 mg and levonorgestrel 0.075 mg [5 white tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 12-21: Ethinyl estradiol 0.03 mg and levonorgestrel 0.125 mg [10 orange tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 light green inactive tablets (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levonest&trade;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-6: Ethinyl estradiol 0.03 mg and levonorgestrel 0.05 mg [6 yellow tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 7-11: Ethinyl estradiol 0.04 mg and levonorgestrel 0.075 mg [5 green tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 12-21: Ethinyl estradiol 0.03 mg and levonorgestrel 0.125 mg [10 light brown tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 white inactive tablets (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myzilra&trade;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-6: Ethinyl estradiol 0.03 mg and levonorgestrel 0.05 mg [6 beige tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 7-11: Ethinyl estradiol 0.04 mg and levonorgestrel 0.075 mg [5 white tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 12-21: Ethinyl estradiol 0.03 mg and levonorgestrel 0.125 mg [10 light yellow tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 light green inactive tablets (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trivora&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-6: Ethinyl estradiol 0.03 mg and levonorgestrel 0.05 mg [6 blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 7-11: Ethinyl estradiol 0.04 mg and levonorgestrel 0.075 mg [5 white tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 12-21: Ethinyl estradiol 0.03 mg and levonorgestrel 0.125 mg [10 pink tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 peach inactive tablets (28s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F168298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16562318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Quartette&trade;: FDA approved March 2013; anticipated availability currently unknown.  Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F168315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer at the same time each day. Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F168314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of pregnancy; postcoital contraception",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F168348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypermenorrhea (menorrhagia); pain associated with endometriosis; dysmenorrhea; dysfunctional uterine bleeding",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F168359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nordette&reg; may be confused with Nicorette&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Portia&reg; may be confused with Potiga&trade;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Seasonale&reg; may be confused with Seasonique&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tri-Levlen&reg; may be confused with Trilafon&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F168349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The following reactions have been associated with oral contraceptive use:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Increased risk or evidence of association with use:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arterial thromboembolism, cerebral hemorrhage, cerebral thrombosis, hypertension, mesenteric thrombosis, MI, venous thrombosis (with or without embolism)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Gallbladder disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatic adenomas, liver tumors (benign)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Retinal thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Adverse reactions considered drug related:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema, varicose vein aggravation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression, migraine, mood changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Chloasma, melasma, rash (allergic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breakthrough bleeding, breast changes (enlargement, pain, secretion, tenderness), carbohydrate tolerance decreased, fluid retention, infertility (temporary), lactation decreased (with use immediately postpartum), menstrual flow changes, spotting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal bloating, abdominal cramps, abdominal pain, appetite changes, nausea, weight changes, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Cervical ectropion, cervical secretion/erosion, endocervical hyperplasia, fibroid enlargement, vaginal candidiasis, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Folate decreased, porphyria exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, focal nodular hyperplasia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chorea exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Contact lens intolerance, corneal curvature changes (steepening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic/anaphylactoid reactions (including angioedema, circulatory collapse, respiratory collapse, urticaria), SLE exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Adverse reactions in which association is not confirmed or denied:",
"     </i>",
"     Acne, auditory disturbances, Budd-Chiari syndrome, cataracts, cervical smear abnormal, colitis, cystitis-like syndrome, dizziness, dysmenorrhea, erythema multiforme, erythema nodosum, headache, hemolytic uremic syndrome, hemorrhagic eruption, hirsutism, libido changes, nervousness, optic neuritis (with or without partial or complete loss of vision), pancreatitis, premenstrual syndrome, renal function impaired, scalp hair loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F168318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breast cancer or other estrogen- or progestin-dependent neoplasms (current or a history of), hepatic tumors or disease, pregnancy, undiagnosed abnormal uterine bleeding",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use is also contraindicated in women at high risk of arterial or venous thrombotic diseases including: Cerebrovascular disease, coronary artery disease, diabetes mellitus with vascular disease, DVT or PE (current or history of), hypercoagulopathies (inherited or acquired), headaches with focal neurological symptoms, hypertension (uncontrolled), migraine headaches if &gt;35 years of age, thrombogenic valvular or rhythm diseases of the heart (eg, subacute bacterial endocarditis with valvular disease or atrial fibrillation), women &gt;35 years of age who smoke.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian-labeling: Additional contraindication: Ocular lesions due to ophthalmic vascular disease including partial or complete loss of vision or defect in visual fields; severe dyslipoproteinemia; hereditary or acquired predisposition for venous or arterial thrombosis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F168302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: Estrogens may induce or exacerbate symptoms in women with hereditary angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer: The use of combination hormonal contraceptives has been associated with a slight increase in frequency of breast cancer; however, studies are not consistent. Use is contraindicated in women with (or history of) breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chloasma: Risk of occurrence may be increased with history of chloasma gravidarum. Women with history of chloasma should avoid exposure to sun or ultraviolet radiation during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestasis: Risk of cholestasis may be increased with previous cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Combination hormonal contraceptives may affect serum triglyceride and lipoprotein levels. Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism: May increase the risk of thromboembolism; discontinue use of combination hormonal contraceptives if an arterial or venous thrombotic event occurs. Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011). Use is contraindicated in women with hypercoagulopathies (inherited or acquired).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal bleeding: Presentation of irregular, unresolving vaginal bleeding warrants further evaluation including endometrial sampling, if indicated,  to rule out malignancy; evaluate hypothalamic-pituitary-function in women with persistent (&ge;6 months) amenorrhea (especially associated with breast secretion) following discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with risk factors for coronary artery disease (eg, hypertension, hypercholesterolemia, morbid obesity, diabetes, or women who smoke); may lead to increased risk of myocardial infarction. May have a dose-related risk of vascular disease and hypertension; women with hypertension should be encouraged to use a nonhormonal form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, epilepsy, migraine, diabetes or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fibroids: Discontinue use with the onset of sudden enlargement, pain, or tenderness of fibroids (leiomyomata).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: May have a dose-related risk of gallbladder disease; may worsen existing gallbladder disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic adenomas: Extremely rare adenomas and focal nodular hyperplasia resulting in fatal intra-abdominal hemorrhage have been reported in association with long-term oral contraceptive use. Presentation of an abdominal mass, acute abdominal pain, or intra-abdominal bleeding warrants further evaluation to rule out source.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Combination hormonal contraceptives may be poorly metabolized in women with hepatic impairment. Discontinue if jaundice develops during therapy or if liver function becomes abnormal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use with caution in patients with a history of migraine. Evaluate new, recurrent, severe or persistent headaches. Use with migraine headaches with or without aura if  &gt;35 years of age is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Women with renal disease should be encouraged to use a nonhormonal form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for use prior to menarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers:",
"     <b>",
"      [U.S. Boxed Warning]: The risk of cardiovascular side effects is increased in women who smoke cigarettes; risk increases with age (especially women &gt;35 years of age) and the number of cigarettes smoked; women who use combination hormonal contraceptives should be strongly advised not to smoke. Use is contraindicated in patients &gt;35 years of age who smoke.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, should be discontinued at least 4 weeks prior to and for 2 weeks following elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tartrazine: Some products may contain tartrazine, which may cause allergic reactions in certain individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extended cycle regimen: Contraceptives with an extended cycle regimen provide more hormonal exposure per year than conventional monthly contraceptives.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV infection protection: Combination hormonal contraceptives do not protect against HIV infection or other sexually-transmitted diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Minimum effective dosage: The minimum dosage combination of estrogen/progestin that will effectively treat the individual patient should be used. New patients should be started on products containing &le;0.035 mg of estrogen per tablet.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F168346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F168307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acitretin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use of a non-hormone-based contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Progestins). Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Armodafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with armodafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Estrogens) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Progestins) may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Progestins). Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with drospirenone. Boceprevir may increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with norethindrone. Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day. Avoid drospirenone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Progestins). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Oral Contraceptive (Progestins). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Estrogens). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with fosaprepitant or aprepitant and for at least one month following the last fosaprepitant/aprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Progestins). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May increase the metabolism of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use an alternative, nonhormonal form of contraception, or use an alternative to griseofulvin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Contraceptives (Estrogens) may decrease the serum concentration of LamoTRIgine.  Management: Monitor for increased serum concentrations/effects of lamotrigine in patients in whom a hormonal contraceptive is discontinued/dose decreased (this includes during a pill-free week). A reduced dosage of lamotrigine may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May decrease the serum concentration of Contraceptives (Progestins). Management: Women using progestin-only &ldquo;minipill&rdquo; products may be at risk for contraceptive failure; it is unclear if other progestin-containing products would be significantly impacted.  Alternative, non-hormonal, means of contraception are recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Estrogens). Mifepristone may increase the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Modafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with modafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Estrogens). Average AUC values were unchanged, but there was evidence of substantial patient-to-patient variability in response to this combination. Management: Women of childbearing potential who are receiving mycophenolate mofetil should consider using an alternative and/or additional form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Progestins). Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Contraceptives (Estrogens). Management: Use of an alternative, nonhormonal form of contraception during nafcillin therapy is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Progestins). Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May decrease the serum concentration of Contraceptives (Progestins). Management: Patients should use an alternative, non-hormonal based form of contraception for the duration of concurrent perampanel.  Both oral and non-oral progestin-based contraceptives are likely to be impacted by this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins). Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Estrogens). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Estrogens) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Progestins) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Consider an alternative to St John's wort if possible.  If this combination is used, an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Consider using a product other than St John's wort.  Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Progestins). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Contraceptives (Estrogens) may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: Contraceptives (Estrogens) may increase the serum concentration of TiZANidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Risk appears greatest for higher topiramate doses (200 mg/day or greater).  Some have recommended using at least 50 mcg/day of ethinyl estradiol, but the effectiveness of this is unclear.  Consider a nonhormonal form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Progestins). Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Progestins) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Estrogens) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Estrogens) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Progestins) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.  Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May decrease the metabolism of Contraceptives (Estrogens). Contraceptives (Estrogens) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F168327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine. Grapefruit juice increases ethinyl estradiol plasma concentrations and would be expected to increase progesterone serum levels as well; clinical implications are unclear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Herbs with estrogenic properties may enhance the adverse/toxic effect of estrogen derivatives; examples include alfalfa, black cohosh, bloodroot, hops, kudzu, licorice, red clover, saw palmetto, soybean, thyme, wild yam, yucca. Herbs with progestogenic properties may enhance the adverse/toxic effect of progestins; examples include bloodroot, chasteberry, damiana, oregano, yucca. Impaired folate metabolism and reduced serum levels of cyanocobalamin have been reported with oral contraceptive use; increased dietary intake or supplementation may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F168309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F168321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy should be ruled out prior to treatment and discontinued if pregnancy occurs. In general, the use of combination hormonal contraceptives when inadvertently taken early in pregnancy have not been associated with teratogenic effects. Hormonal contraceptives may be less effective in obese patients. An increase in oral contraceptive failure was noted in women with a BMI &gt;27.3 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Similar findings were noted in patients weighing &ge;90 kg (198 lb) using the contraceptive patch.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to increased risk of venous thromboembolism (VTE) postpartum, combination hormonal contraceptives should not be started in any woman &lt;21 days following delivery. Women without risk factors for VTE and who are not breast-feeding may start combination hormonal contraceptives during 21-42 days postpartum. After 42 days postpartum, restrictions for use are not related to postpartum status and should be based on other medical conditions (CDC,  2011).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F168340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F168322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Jaundice and breast enlargement in the nursing infant have been reported following the use of combination hormonal contraceptives. May decrease the quality and quantity of breast milk; alternative form of contraception is recommended (per manufacturer). The theoretical concerns about decreased milk production are greatest early in the postpartum period when milk production is being established. Postpartum risk status for VTE should be considered when initiating combination hormonal contraceptives after delivery. Combined hormonal contraceptives should not be started &lt;21 days postpartum due to increased risk of VTE. Risk of VTE is still elevated in breast-feeding women until ~42 days postpartum and is greater in women with additional risk factors. After 42 days postpartum, restrictions for use are not related to postpartum VTE risk and should be based on other medical conditions (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F168323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken at the same time each day.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F168320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Altavera Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-30 mg-mcg (28): $30.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Amethia Lo Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1-0.02 &amp; 0.01 mg (91): $268.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Amethia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-0.03 &amp;0.01 mg (91): $268.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Amethyst Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90-20 mcg (28): $59.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Aviane Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1-20 mg-mcg (28): $35.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Camrese Lo Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1-0.02 &amp; 0.01 mg (91): $268.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Camrese Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-0.03 &amp;0.01 mg (91): $268.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Chateal Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-30 mg-mcg (28): $9.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Falmina Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1-20 mg-mcg (28): $35.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Introvale Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-0.03 mg (91): $160.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Jolessa Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-0.03 mg (91): $160.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Kurvelo Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-30 mg-mcg (28): $30.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lessina Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1-20 mg-mcg (28): $34.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Levonorgest-Eth Estrad 91-Day Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1-0.02 &amp; 0.01 mg (91): $268.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-0.03 mg (91): $160.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Levonorgestrel-Ethinyl Estrad Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1-20 mg-mcg (28): $35.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-30 mg-mcg (28): $30.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Levora 0.15/30 (28) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-30 mg-mcg (28): $30.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (LoSeasonique Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1-0.02 &amp; 0.01 mg (91): $298.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lutera Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1-20 mg-mcg (28): $35.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nordette (28) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-30 mg-mcg (28): $107.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Orsythia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1-20 mg-mcg (28): $35.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Portia-28 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-30 mg-mcg (28): $30.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Quasense Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-0.03 mg (91): $160.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Seasonique Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-0.03 &amp;0.01 mg (91): $298.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sronyx Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1-20 mg-mcg (28): $35.16",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F168311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before starting therapy, a physical exam with reference to the breasts and pelvis are recommended, including a Papanicolaou smear. Exam may be deferred if appropriate; pregnancy should be ruled out prior to use. Monitor patient closely for loss of vision, sudden onset of proptosis, diplopia, migraine; blood pressure; signs and symptoms of thromboembolic disorders; signs or symptoms of depression; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F168324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anulette (CN, PE, PY);",
"     </li>",
"     <li>",
"      Biphasil (ZA);",
"     </li>",
"     <li>",
"      Ciclo 21 (BR);",
"     </li>",
"     <li>",
"      Daily Ge (FR);",
"     </li>",
"     <li>",
"      E-Gen-C (ZA);",
"     </li>",
"     <li>",
"      Evelea MD (AR);",
"     </li>",
"     <li>",
"      Gynatrol (DK);",
"     </li>",
"     <li>",
"      Klimonorm (HK);",
"     </li>",
"     <li>",
"      Lady (PH);",
"     </li>",
"     <li>",
"      Levlen ED (AU, NZ);",
"     </li>",
"     <li>",
"      Lindella (CO);",
"     </li>",
"     <li>",
"      Lindella CD (CO);",
"     </li>",
"     <li>",
"      Loette (HK, IN, MY, NZ, SG);",
"     </li>",
"     <li>",
"      Loette 21 (SG);",
"     </li>",
"     <li>",
"      Logynon (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, PH, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Logynon ED (AU, ZA);",
"     </li>",
"     <li>",
"      Ludeal Ge (FR);",
"     </li>",
"     <li>",
"      Microfemin (CO);",
"     </li>",
"     <li>",
"      Microfemin CD (CO);",
"     </li>",
"     <li>",
"      Microgyn (DK);",
"     </li>",
"     <li>",
"      Microgynon (CO, CR, CZ, DK, DO, EC, FI, GR, GT, HN, ID, IL, IT, MX, NI, NO, PA, PE, PH, RU, SV, UY);",
"     </li>",
"     <li>",
"      Microgynon 20 ED (AU, NZ);",
"     </li>",
"     <li>",
"      Microgynon 21 (DE, PL);",
"     </li>",
"     <li>",
"      Microgynon 28 (DE);",
"     </li>",
"     <li>",
"      Microgynon 30 (AE, AT, AU, BE, BF, BH, BJ, CH, CI, CY, DO, EG, ET, GB, GH, GM, GN, HK, IE, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Microgynon 30 ED (AU, BB, BM, BS, BZ, GY, HK, JM, NZ, PR, SR, TH, TT);",
"     </li>",
"     <li>",
"      Microgynon CD (CO, DO, EC, MX);",
"     </li>",
"     <li>",
"      Microlenyn 30 ED (TH);",
"     </li>",
"     <li>",
"      Minidril (FR);",
"     </li>",
"     <li>",
"      Monofeme (NZ);",
"     </li>",
"     <li>",
"      Neogynon 21 (DE);",
"     </li>",
"     <li>",
"      Nordet (MX);",
"     </li>",
"     <li>",
"      Nordette (AR, BF, BJ, CI, CN, CO, ET, GH, GM, GN, GR, HK, IL, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, PH, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Nordette 21 (NZ, TH);",
"     </li>",
"     <li>",
"      Nordette 28 (AU, NZ, TH);",
"     </li>",
"     <li>",
"      Norvetal (CO);",
"     </li>",
"     <li>",
"      Novastep (DE);",
"     </li>",
"     <li>",
"      Oralcon (MY);",
"     </li>",
"     <li>",
"      Ovoplex 30-150 (ES);",
"     </li>",
"     <li>",
"      Ovranette (AT, GB);",
"     </li>",
"     <li>",
"      Rigevidon (AE, BH, CY, EG, GB, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Rigevidon 21+7 (HK, MY);",
"     </li>",
"     <li>",
"      Safe Pill (PH);",
"     </li>",
"     <li>",
"      Seif (PH);",
"     </li>",
"     <li>",
"      Stediril 30 (BE, CZ, NL);",
"     </li>",
"     <li>",
"      Triciclor (ES);",
"     </li>",
"     <li>",
"      Trifeme (NZ);",
"     </li>",
"     <li>",
"      Trifeme 28 (AU);",
"     </li>",
"     <li>",
"      Trigoa (DE);",
"     </li>",
"     <li>",
"      Trigynon (AT, BE);",
"     </li>",
"     <li>",
"      Trinordiol (AR, AT, BE, BF, BJ, BR, CI, CN, CZ, DE, DK, ET, FI, GH, GM, GN, GR, HK, IE, IT, KE, LR, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, PH, PL, RU, SC, SD, SE, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Trinordiol 21 (DE);",
"     </li>",
"     <li>",
"      Triphasil (NZ, ZA);",
"     </li>",
"     <li>",
"      Triphasil 28 (AU, NZ);",
"     </li>",
"     <li>",
"      Triquilar (AE, BH, CL, CY, CZ, DE, DO, EC, EG, GR, IN, IQ, IR, JO, KP, KW, LB, LY, MX, OM, PY, QA, SA, SY, UY, VE, YE);",
"     </li>",
"     <li>",
"      Triquilar ED (AU, ID, MY, NZ, TH);",
"     </li>",
"     <li>",
"      TriRegol (GB);",
"     </li>",
"     <li>",
"      Trolit (PE);",
"     </li>",
"     <li>",
"      Winstop 30 (TW);",
"     </li>",
"     <li>",
"      Winstop T/28 (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F168301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination hormonal contraceptives inhibit ovulation via a negative feedback mechanism on the hypothalamus, which alters the normal pattern of gonadotropin secretion of a follicle-stimulating hormone (FSH) and luteinizing hormone by the anterior pituitary. The follicular phase FSH and midcycle surge of gonadotropins are inhibited. In addition, combination hormonal contraceptives produce alterations in the genital tract, including changes in the cervical mucus, rendering it unfavorable for sperm penetration even if ovulation occurs. Changes in the endometrium may also occur, producing an unfavorable environment for nidation. Combination hormonal contraceptive drugs may alter the tubal transport of the ova through the fallopian tubes. Progestational agents may also alter sperm fertility.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F168317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Ethinyl estradiol: 4.3 L/kg; Levonorgestrel: 1.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ethinyl estradiol: 95% to 97% to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levonorgestrel: 97% to 99% primarily to sex hormone binding globulin (SHBG), lesser amounts to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ethinyl estradiol: Hepatic via CYP3A4; undergoes first-pass metabolism; forms metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levonorgestrel: Forms conjugated in unconjugated metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Ethinyl estradiol: 38% to 48%; Levonorgestrel: 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Ethinyl estradiol: 12-23  hours; Levonorgestrel: 22-49 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ethinyl estradiol: Urine and feces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levonorgestrel: Urine (40% to 68%, parent drug and metabolites); feces (16% to 48% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson FD, Gibbons W, and Portman D, &ldquo;Safety and Efficacy of an Extended-Regimen Oral Contraceptive Utilizing Continuous Low-Dose Ethinyl Estradiol,&rdquo;",
"      <i>",
"       Contraception",
"      </i>",
"      , 2006, 73(3):229-234.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/2/17450/abstract-text/16472561/pubmed\" id=\"16472561\" target=\"_blank\">",
"        16472561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Archer DF, Jensen JT, Johnson JV, et al, &ldquo;Evaluation of a continuous Regimen of Levonorgestrel/Ethinyl Estradiol: Phase 3 Study Results,&rdquo;",
"      <i>",
"       Contraception",
"      </i>",
"      , 2006 74(6):439-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/2/17450/abstract-text/17157099/pubmed\" id=\"17157099\" target=\"_blank\">",
"        17157099",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burkman R, Schlesselman JJ, and Zieman M, &ldquo;Safety Concerns and Health Benefits Associated With Oral Contraception,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2004, 190(4 Suppl):5-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/2/17450/abstract-text/15105794/pubmed\" id=\"15105794\" target=\"_blank\">",
"        15105794",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: Revised Recommendations for the Use of Contraceptive Methods During the Postpartum Period,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(26):878-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/2/17450/abstract-text/21734635/pubmed\" id=\"21734635\" target=\"_blank\">",
"        21734635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/2/17450/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. Panel on Clinical Practices for Treatment of HIV Infection,&rdquo; August 13, 2001. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holt VL, Scholes D, Wicklund KG, et al, &ldquo;Body Mass Index, Weight, and Oral Contraceptive Failure Risk,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 105(1):46-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/2/17450/abstract-text/15625141/pubmed\" id=\"15625141\" target=\"_blank\">",
"        15625141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orme ML, Back DJ, and Breckenridge AM, &ldquo;Clinical Pharmacokinetics of Oral Contraceptive Steroids,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1983, 8(2):95-136.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/2/17450/abstract-text/6342899/pubmed\" id=\"6342899\" target=\"_blank\">",
"        6342899",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shenfield GM and Griffin JM, &ldquo;Clinical Pharmacokinetics of Contraceptive Steroids. An Update,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1991, 20(1):15-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/2/17450/abstract-text/2029800/pubmed\" id=\"2029800\" target=\"_blank\">",
"        2029800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitruk-Ware R and Nath A, \"Metabolic Effects of Contraceptive Steroids,\"",
"      <i>",
"       Rev Endocr Metab Disord",
"      </i>",
"      , 2011, 12(2):63-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/2/17450/abstract-text/21538049/pubmed\" id=\"21538049\" target=\"_blank\">",
"        21538049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/2/17450/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9435 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-4F9416D058-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_2_17450=[""].join("\n");
var outline_f17_2_17450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708763\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168331\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168332\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168351\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168335\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168345\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168336\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168337\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168313\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168298\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16562318\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168315\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168314\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168348\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168359\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168349\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168318\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168302\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168346\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168307\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168327\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168309\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168321\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168340\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168322\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168323\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168320\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168311\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168324\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168301\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168317\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9435\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9435|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/43/22198?source=related_link\">",
"      Ethinyl estradiol and levonorgestrel: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_2_17451="Pre BMT risk class in beta thal";
var content_f17_2_17451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Predictive variables of outcome after bone marrow transplantation in patients with beta thalassemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk factor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse",
"       </td>",
"       <td class=\"subtitle1\">",
"        Favorable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatomegaly (cm from costal arch)",
"       </td>",
"       <td>",
"        &gt;2 cm",
"       </td>",
"       <td>",
"        &le;2 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver fibrosis",
"       </td>",
"       <td>",
"        Presence",
"       </td>",
"       <td>",
"        Absence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron chelation therapy",
"       </td>",
"       <td>",
"        Irregular",
"       </td>",
"       <td>",
"        Regular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Risk class",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        Class 1 patients have all three favorable risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        Class 2 patients have one or two adverse risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        Class 3 patients have all three adverse risk factors",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_2_17451=[""].join("\n");
var outline_f17_2_17451=null;
var title_f17_2_17452="Differential diagnosis of DLBCL";
var content_f17_2_17452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F56467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F56467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of diffuse large B-cell lymphoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Entity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Histology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Immunophenotype",
"       </td>",
"       <td class=\"subtitle1\">",
"        Genetic features/other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diffuse large B-cell lymphoma",
"       </td>",
"       <td>",
"        Large, transformed B-cells with prominent nucleoli and basophilic cytoplasm, a diffuse growth pattern and a high proliferation (Ki-67+) fraction.",
"       </td>",
"       <td>",
"        Generally express pan B-cell antigens (CD19, CD20, CD22, CD79a).",
"       </td>",
"       <td>",
"        The majority has genetic abnormalities, but there is no single cytogenetic change that is typical or diagnostic.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Burkitt lymphoma",
"       </td>",
"       <td>",
"        Monomorphic, medium-sized cells with round nuclei, multiple nucleoli, basophilic cytoplasm, prominent cytoplasmic lipid vacuoles, and a \"starry-sky\" pattern. Ki-67+ fraction approaching 100 percent.",
"       </td>",
"       <td>",
"        Express surface IgM and B-cell-associated antigens (CD19, CD20, CD22, CD79a), as well as CD10, HLA-DR, and CD43. They lack CD5, bcl-2, and typically lack CD23.",
"       </td>",
"       <td>",
"        Strongly (but not uniformly) associated with a translocation between the long arm of chromosome 8, the site of the c-MYC oncogene (8q24), and one of three locations on Ig genes: t(8;14), t(2;8), or t(8;22).",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Anaplastic large cell lymphoma",
"       </td>",
"       <td>",
"        Large cells with horseshoe-shaped or embryoid nuclei, prominent nucleoli, and abundant cytoplasm. Often shows a cohesive growth pattern.",
"       </td>",
"       <td>",
"        Homogeneous and strong expression of CD30 in a membrane and golgi pattern. Usually express one or more T-cell antigens (ie, CD2, CD3, CD5, CD7). Do not express B-cell antigens.",
"       </td>",
"       <td>",
"        Two distinct subtypes: ALK positive (detected by immunostains or molecular genetics) and ALK negative.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hodgkin lymphoma",
"       </td>",
"       <td>",
"        Lymphocyte predominant or lymphocyte rich classical Hodgkin lymphoma (HL) can morphologically resemble T-cell histiocyte rich large B-cell lymphoma. The HL tumor contains a minority of neoplastic cells (Reed-Sternberg cells and their variants) in an inflammatory background.",
"       </td>",
"       <td>",
"        The neoplastic cells typically express CD15 and CD30, variably express CD20, and do not express CD3 or CD45.",
"       </td>",
"       <td>",
"        There is no single cytogenetic change that is typical or diagnostic.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_2_17452=[""].join("\n");
var outline_f17_2_17452=null;
var title_f17_2_17453="Dietary fiber in foods";
var content_f17_2_17453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Amount of dietary fiber in common foods",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            &ge;4 g/serving",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            All bran (1/3 cup)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Blackberries (3/4 cup)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bran Buds",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bran Chex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Corn Bran",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fiber One",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            100 percent Bran",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Raspberries (1 cup)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Wheat bran (unprocessed or miller's, 1 tbsp)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Wheatena, cooked",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            2 or 3 g/serving",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beans, baked (canned, 1/4 cup)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Boysenberries (1/3 cup)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bran flakes, 40 percent",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Raisin bran",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ry-Krisp (3 triple crackers)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bran muffin (1 average)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Oat bran (cooked)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Peas, dried (cooked, 1/3 cup)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Popcorn, popped (3 cups)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pumpkin (3 cups)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Whole-wheat bread, roll, or bun (1 piece)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            1 g/serving",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Fruits",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Apricot",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Apple",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Grapefruit",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Melon",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Orange",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Peach",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pear",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pineapple",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Vegetables products",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Asparagus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Beans (string)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Broccoli",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Beets",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Carrots",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cauliflower",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Greens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Whole-grain",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Granola",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Oatmeal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pasta (from whole-wheat flour)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Total",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Wheat Chex",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     One serving equals 1/2 cup unless noted.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Gastroenterological Association. Gastroenterology 2000; 119:1766.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_2_17453=[""].join("\n");
var outline_f17_2_17453=null;
var title_f17_2_17454="Kaplan Meier plots ophtha";
var content_f17_2_17454=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F52658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F52658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Development or progression of ophthalmopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 377px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    443 patients with Graves' hyperthyroidism were randomly assigned to receive radioiodine, radioiodine followed by a 3-month course of prednisone, or methimazole for 18 months. Development or worsening of ophthalmopathy occurred more often in the radioiodine than in the methimazole group. Worsening of ophthalmopathy was prevented by the administration of prednisone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bartalena, L, Marcocci, C, Bogazzi, F, et al, N Engl J Med 1998; 338:73.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_2_17454=[""].join("\n");
var outline_f17_2_17454=null;
var title_f17_2_17455="Fetal bilateral schizencephaly";
var content_f17_2_17455=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F83167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F83167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fetal bilateral schizencephaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 140px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnetic resonance image of a fetus with bilateral schizencephaly and agenesis of the septi pellucidi.",
"    <br/>",
"    (A) Axial section showing the bilateral defect (arrows).",
"    <br/>",
"    (B) Anterior coronal section showing the left sided defect (arrow).",
"    <br/>",
"    (C) More posterior coronal section showing the defect on the right side of the brain (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sarah S Milla, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_2_17455=[""].join("\n");
var outline_f17_2_17455=null;
